The HMC18 breast cancer cell line was derived from the pleural effusion metastasis of a primary ductal breast carcinoma of a 35 year old Asian (Japanese) female. The breast cancer and cell line is ER and HER2 negative and has been classified at a Basal B type cell line. The STR profile and other genomic information pertinent to this cell line can be found here at Cellosaurus or here at DepMap Portal. There is no entry for this cell line in COSMIC.
Oncogene Signature: Given the oncogene signature of this cell line, it is not surprising that it has been classified as a highly aggressive Basal B type cell line. The KRAS point mutation coupled with the TP53 mutations is a strong signature for a highly aggressive type of cancer. It is worth noting that, using the Gene Query tool on the SLKBase, it can be seen that these cells also highly overexpress the MYC oncogene, even though the gene is not amplified in these cells. The absence of MYC amplification is why the gene does not appear in the Oncogene Signature (though it probably should). The MYC gene was also a strong hit in the CRISPR screen. All in all, this is a classic KRAS/MYC/TP53 breast transformed cell line.
| Gene | CRISPR score | Demeter score | Log fold change | DNA amp | mutation | occ. In Cosmic |
| KRAS | -1.726078095 | 0.66211081 | 0.22758 | p.G12V | 15813 | |
| TP53 | 0.028597677 | -3.121159322 | -0.220448 | p.P153fs | 132 |
There are currently no data on drug sensitivity for this breast cancer cell line in the GDSC1 or 2 databases.
